NASDAQ · LBRX
Healthcare · Biotechnology
$39.70
Down-$0.45 (-1.12%)
Updated Nov 1, 2026, 5:59 AM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LBRX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
LBRX closed at $39.70 after 20 trading sessions, up 14.67% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $40.10 | $41.2362 | $39.125 | $39.70 | 429.47K |
| Oct 29, 2026 | $39.80 | $40.76 | $39.225 | $40.15 | 400.68K |
| Oct 28, 2026 | $39.53 | $40.38 | $38.49 | $39.83 | 201.74K |
| Oct 27, 2026 | $39.14 | $40.345 | $38.578 | $39.64 | 236.35K |
| Oct 26, 2026 | $39.07 | $41.047 | $38.445 | $39.34 | 275.98K |
| Oct 23, 2026 | $39.25 | $39.73 | $38.26 | $38.73 | 188.57K |
| Oct 22, 2026 | $39.12 | $41.58 | $38.3912 | $39.42 | 230.85K |
| Oct 21, 2026 | $41.10 | $41.24 | $39.04 | $39.23 | 247.16K |
| Oct 20, 2026 | $38.88 | $41.42 | $38.24 | $41.00 | 388.49K |
| Oct 19, 2026 | $36.91 | $40.10 | $36.03 | $38.81 | 588.52K |
| Oct 16, 2026 | $36.62 | $37.37 | $36.06 | $36.74 | 724.81K |
| Oct 15, 2026 | $34.54 | $37.43 | $34.50 | $36.69 | 976.65K |
| Oct 14, 2026 | $34.10 | $35.51 | $33.8833 | $34.00 | 362.71K |
| Oct 13, 2026 | $36.10 | $36.10 | $34.44 | $34.79 | 297.41K |
| Oct 12, 2026 | $37.26 | $37.43 | $34.54 | $35.93 | 491.51K |
| Oct 9, 2026 | $35.01 | $38.50 | $35.01 | $37.22 | 642.58K |
| Oct 8, 2026 | $33.83 | $35.725 | $33.13 | $34.61 | 440.67K |
| Oct 7, 2026 | $34.02 | $36.57 | $34.00 | $34.16 | 385.03K |
| Oct 6, 2026 | $35.25 | $35.59 | $33.7266 | $34.26 | 432.77K |
| Oct 5, 2026 | $36.41 | $36.88 | $34.47 | $34.62 | 494.49K |
The latest Smart Investors Daily articles mentioning LBRX.
Company
Market Activity
Research & News
LBRX research
Company profile and research snapshot.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 9, 2026 | Canaccord Genuity | Buy | — |
| Oct 6, 2026 | Guggenheim | Buy | — |
| Oct 5, 2026 | Roth Capital | Neutral | — |
| Oct 2, 2026 | Needham | Buy | — |
| Aug 24, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 28, 2026
Guggenheim Securities reiterated its buy rating on LB Pharmaceuticals and named the biotechnology company a top investment idea, citing promising clinical data for its experimental schizophrenia drug LB-102 and potential expansion into mood disorders ahead of a pivotal trial readout expected in the first half of 2027.
Yahoo · Oct 28, 2026
LB Pharmaceuticals (NASDAQ:LBRX) outlined its clinical and commercial plans for LB-102, an investigational antipsychotic designed as a structural modification of amisulpride, during its first R&D Day in New York. The company said it expects three clinical readouts over the next three years, begi
Yahoo · Oct 15, 2026
NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain disorders, today announced that members of its executive team will present and participate in the following upcoming investor conferences: Craig-Hallum Biotech Catalyst Conference Virtual fireside chat at 10:00 a.m. ET and virtu
Yahoo · Oct 11, 2026
LB Pharmaceuticals has seen its analyst fair value estimate move from US$53.38 to US$58.00, an adjustment of about 8.7% that puts fresh attention on the stock. Analysts link this change to evolving views on LB-102, as they weigh perceived clinical de-risking against questions on long term commercial positioning and valuation. Read on to see what is driving the updated narrative and how you can track these shifts over time. Stay updated as the Fair Value for LB Pharmaceuticals shifts by adding...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LBRX.
